circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-02. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
== Dosing == As dosage regimens for treating leishmaniasis have evolved, the daily dose of antimony and the duration of therapy have been progressively increased to combat unresponsiveness to therapy. In the 1980s, the use of 20 mg/kg/day (instead of 10 mg/kg/day) of antimony was recommended, but only to a maximum daily dose of 850 mg. Recent research has suggested on the basis of recent efficacy and toxicity data that this 850-mg restriction should be removed. The evidence to date, which is in their research, suggests that a regimen of 20 mg/kg/day of pentavalent antimony, without an upper limit on the daily dose, is more efficacious and is not substantially more toxic than regimens with lower daily doses. It is recommend treating all forms of leishmaniasis with a full 20 mg/kg/day of pentavalent antimony. Treatment of cutaneous leishmaniasis usually lasts for 20 days and visceral and mucosal leishmaniasis for 28 days. The dose of sodium stibogluconate is by slow intravenous infusion (at least five minutes with cardiac monitoring). The injection are stopped if there is coughing or central chest pain. The chemotherapeutic index was established by Leonard Goodwin during the Second World War when a treatment was urgently required for Allied troops during the invasion of Sicily. The duration of treatment is usually 10 to 21 days and depends on the species of Leishmania and the type of infection (cutaneous or visceral).
=== Positions of employment === 1982-1985 Instructor and assistant. Associate Professor, University of Copenhagen 1986-1987 Clinical Department Ph.D. scholarship, University of Copenhagen 1987-1988 Department of Pharmacology Ph.D. scholarship, University of Copenhagen 1988 - 1991 Pharmacologist at LEO Pharma 1991 - 2000 Management positions at Novo Nordisk, from 1994 as research director 1991 – 1993 Head of growth hormone pharmacology, Biopharmaceuticals Division, Novo Nordisk 1993 – 1994 Director of pharmacology, Diabetes Care Division, Novo Nordisk 1994 – 1995 Senior vice president of diabetes research & development, Diabetes Care Division, Novo Nordisk 1995 – 1998 Corporate vice president of Drug Discovery, Novo Nordisk 1998 – 2000 Corporate vice president of drug discovery and preclinical development, Novo Nordisk 2000 – 2021 Group vice president of research and development, Novo Nordisk 2000 – adjunct professor of pharmacology, University of Copenhagen 2021 - CEO, Novo Nordisk Foundation
== Science and technology == Rational polynomial coefficient Reactive Plastic Curtain, a carbon-dioxide-absorbing device used in some rebreather breathing sets Regional Playback Control, a regional lockout technology for DVDs Remote procedure call, an inter-process communication technique in networked computing Open Network Computing Remote Procedure Call, IETF RPC, a.k.a. "Sun RPC" DCE/RPC, for Distributed Computing Environment by Open Software Foundation JSON-RPC, a "JSON encoded" variant XML-RPC, an "XML encoded" variant Resistive plate chamber, a simple type of particle detector used in experimental particle physics Reversed-phase chromatography, a chemistry technique Acorn Risc PC Rocket Pod Container, the interchangeable containers used to transport and launch missiles for use with the M270 Multiple Launch Rocket System Rotary phase converter, an electrical machine that converts power from one polyphase system (including frequency) to another, converting through rotary motion.
=== Money laundering === Criminal networks often launder their money in Morocco, southern Spain, or Dubai. This illegal money often circulates through the Hawala system, a parallel banking system of Arab origin that is often used by organised crime syndicates. Interpol also mentioned that the Moroccan mafia has a major involvement in the synthetic drug market, particularly in the manufacturing of these drugs, as well as playing an important role in the trafficking of cannabis (hashish) from the Jbala region in Morocco. In Wouter Laumans' book on the Moroccan mafia, he cites that 80% of northern Morocco is built with illegal money that mostly originates from money laundering. Dutch investigator Pieter Tops made an astonishing discovery in September 2018: trafficking networks in the Netherlands easily collect up to €20 billion through the trade of synthetic drugs such as XTC or amphetamines. Tops warned the Belgian authorities that the traffickers have so much money re-invested in legal businesses, which seriously affects the communities and neighbourhoods from where these traffickers originate. As mayor of Antwerp, Bart De Wever asked for reinforcements to investigate the drug trade and the Moroccan mafia in the city, to intercept a maximum number of people who are involved in these drug trafficking businesses.
== Applications == There are five major areas where protein arrays are being applied: diagnostics, proteomics, protein functional analysis, antibody characterization, and treatment development. Diagnostics involves the detection of antigens and antibodies in blood samples; the profiling of sera to discover new disease biomarkers; the monitoring of disease states and responses to therapy in personalized medicine; the monitoring of environment and food. Digital bioassay is an example of using protein microarray for diagnostic purposes. In this technology, an array of microwells on a glass/polymer chip are seeded with magnetic beads (coated with fluorescent tagged antibodies), subjected to targeted antigens and then characterised by a microscope through counting fluorescing wells. A cost-effective fabrication platform (using OSTE polymers) for such microwell arrays has been recently demonstrated and the bio-assay model system has been successfully characterised. Proteomics pertains to protein expression profiling i.e. which proteins are expressed in the lysate of a particular cell. Protein functional analysis is the identification of protein–protein interactions (e.g. identification of members of a protein complex), protein–phospholipid interactions, small molecule targets, enzymatic substrates (particularly the substrates of kinases) and receptor ligands. Antibody characterization is characterizing cross-reactivity, specificity and mapping epitopes.
Sources: en.wikipedia.org
==== Metabolism ==== Atenolol undergoes minimal or negligible metabolism by the liver. It has been estimated that about 5% of atenolol is metabolized. This is in contrast to other beta blockers like propranolol and metoprolol, but is similar to nadolol. In accordance with its lack of hepatic metabolism, the pharmacokinetics of atenolol are not altered in hepatic impairment, unlike the case of propranolol. Two metabolites of atenolol have been identified: hydroxyatenolol and atenolol glucuronide. It has been said that it is unknown if these metabolites are active. However, another source stated that hydroxyatenolol has one-tenth the beta-blocking activity of atenolol.
Canning involves cooking food, sealing it in sterilized cans or jars, and boiling the containers to kill or weaken any remaining bacteria as a form of sterilization. It was invented by the French confectioner Nicolas Appert. By 1806, this process was used by the French Navy to preserve meat, fruit, vegetables, and even milk. Although Appert had discovered a new way of preservation, it was not understood until 1864 when Louis Pasteur found the relationship between microorganisms, food spoilage, and illness. Foods have varying degrees of natural protection against spoilage and may require that the final step occurs in a pressure cooker. High-acid fruits like strawberries require no preservatives to can and only a short boiling cycle, whereas marginal vegetables such as carrots require longer boiling and the addition of other acidic elements. Low-acid foods, such as vegetables and meats, require pressure canning. Food preserved by canning or bottling is at immediate risk of spoilage once the can or bottle has been opened. Lack of quality control in the canning process may allow ingress of water or micro-organisms. Most such failures are rapidly detected as decomposition within the can cause gas production and the can will swell or burst. However, there have been examples of poor manufacture (underprocessing) and poor hygiene allowing contamination of canned food by the obligate anaerobe Clostridium botulinum, which produces an acute toxin within the food, leading to severe illness or death.
=== Violence === The heightened levels of violence and abuse that transgender people experience result in unique adverse effects on bodily and mental health. Specifically, in resource-constrained settings where non-discriminatory policies may be limited or not enforced, transgender people may encounter high rates of stigma and violence which are associated with poor health outcomes. Studies in countries of the Global North show higher levels of discrimination and harassment in school, workplace, healthcare services and the family when compared with cisgender populations, situating transphobia as a key health risk factor for the physical and mental health of transgender people. Victimization is often the outcome to disclosure for transgender individuals. Transgender individuals are pressured to conform to gender norms which make them vulnerable for victimization by peers and parents. A study done by Grossman and D'Augelli reported that transgender youth feared that may face physical and sexual violence because of their experience with harassment and discrimination. The youth also express how individuals only see them for their gender and sexuality rather than their personal traits. Many of the youth have also dropped out or experience academic decline because of the constant harassment. Victimization started on average for transgender at the age of 13, while physical abuse started at an average age 14.
==== De-epithelialization technique ==== Labial reduction by means of the de-epithelialization of the tissues involves cutting the epithelium of a central area on the medial and lateral aspects of each labium minus (small lip), either with a scalpel or with a medical laser. This labiaplasty technique reduces the vertical excess tissue, whilst preserving the natural rugosity (corrugated free-edge) of the labia minora, and thus preserves the sensory and erectile characteristics of the labia. Yet, the technical disadvantage of de-epithelialization is that the width of the individual labium might increase if a large area of labial tissue must be de-epithelialized to achieve the labial reduction.
Sources: en.wikipedia.org
One of these strains was used for creation of replication deficient SeV85AB construct that is lacking fusion protein (F) but has inserted sequence encoding immunodominant antigen of Mycobacterium tuberculosis. The safety and immunogenicity of this construct was tested in animal models. This construct can be easily transformed into the construct that encodes S-protein of SARS-CoV-2. In Russia, State Research Center of Virology and Biotechnology VECTOR is in developing stage of vaccine against COVID-19 using Moscow strain of Sendai virus as a vector backbone. In Japan researchers have developed two intranasal vaccine candidates against SARS-CoV-2. One design utilizes a modified Sendai virus (SeV) as a vector to deliver the SARS-CoV-2 spike protein's receptor binding domain (RBD) directly to the respiratory tract. In pre-clinical studies, mice received the vaccine intranasally. Mice demonstrated elevated levels of antibodies specific to the SARS-CoV-2 S-RBD (IgM, IgG, IgA) in both their blood serum and bronchoalveolar lavage fluid, lasting up to 12 weeks. Another design uses a similar F-gene lacking SeV vector but different SARS-CoV-2 antigens. Instead of the S-protein, the vaccine design used SARS-CoV-2 nucleocapsid (N), membrane (M), and envelope (E) proteins as immunogens. The study found strong CD8+ T cell responses against these antigens, suggesting intranasal vaccination can trigger immune cells (CD8+ T cells) that target the virus and help control SARS-CoV-2 infection.
Many vulture species are obligately necrophagous including the bearded vulture, black vulture, cinereous vulture, Eurasian griffon, Himalayan vulture, king vulture and turkey vulture. Types of carrion fed upon include dead wildlife, livestock, poultry and companion animals, human remains (sky burial), hunting discards, slaughterhouse offal and roadkill. Typically, muscle tissue is consumed, but bearded vultures feed on bones and bone marrow. In addition to eating carrion, Egyptian vultures feed on small live animals such as turtles, eggs and rotting fruit. Vultures have many adaptations that help them detect, locate and consume carrion. For example, all vultures have keen eyesight, and New World vultures have a highly developed sense of smell. Hooded vultures also have excellent auditory perception, enabling them to hear distant predation-related noises and the distress calls of dying animals. In addition, gliding flight enables vultures to cover long distances to reach carrion, strong beaks allow vultures to cut through thick animal skin, and strong immune defenses protect vultures from pathogens in carrion. Given the inherently unpredictable and ephemeral nature of carrion as a food source, the ability of vultures to survive long periods between meals is also advantageous. Some human activities have had an adverse impact on vultures in Sicily, the Azerbaijan Republic and other countries.
== Packaging == Centralized cutting and processing of meats has the potential of reducing the shelf life of the cuts. Specialized packaging is needed to regain and even extend that shelf life. Packaging includes tray, absorbent pad (meat diaper), specialty plastic films, etc. Oxygen scavengers and modified atmosphere packaging are used to keep the products visually appealing and consumer safe.
== History == In 1972 England's Whitbread company and the British Royal Naval Sailing Association agreed to sponsor a globe-circling regatta, which would be called the 'Whitbread Round the World Yacht Race'.
Norris was convicted by an 11-1 majority verdict on 3 March 2008 for the murder of four women, and the attempted murder of a fifth (Vera Wilby, aged 90). He was sentenced the following day to life imprisonment, and ordered to serve a minimum term of 30 years in prison. Norris had acted particularly aggressively throughout the trial, banging on the windows of the judge and attacking members of the press when departing the court, shoving two against a wall. Pictures of these attacks were not shown on television for fear of influencing the jury. The judge told Norris when sentencing: "You are, I have absolutely no doubt, a thoroughly evil and dangerous man. You are an arrogant and manipulative man with a real dislike of elderly patients. The most telling evidence was that observation of one of your patients, Bridget Tarpey, who said 'he did not like us old women'. My view is you did not like them because they required too much nursing and were too demanding of your time. You are in my judgment essentially lazy as evidenced by your absences from student placements and work." Norris's mother June Morrison said he had made her so proud as he grew to be successful in his chosen profession. Referred to in the British press as the "Angel of Death", Norris was convicted of killing his victims by injecting them with high levels of insulin. The four victims were:
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.